Trial Profile
A multicenter, randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of two fixed doses (200 Mg or 400 Mg) of DVS-233 SR [desvenlafaxine] in adult outpatients with major depressive disorder.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2009
Price :
$35
*
At a glance
- Drugs Desvenlafaxine (Primary)
- Indications Depression; Major depressive disorder
- Focus Therapeutic Use
- 13 Jul 2006 Results have been reported.
- 08 Oct 2005 New trial record.